Who We Are
We are focused on disrupting heart valve disease and restoring healthy heart function. Our team focuses on tackling clinical gaps and redefining positive outcomes by developing cutting-edge solutions designed to mimic the heart’s native physiology.
News, Presentations and Interviews
News, Presentations and Interviews
The recording of our Annual General Meeting is now available for viewing. This comprehensive session includes detailed discussions, strategic updates, and future plans that underscore the continued growth and innovation at Anteris Technologies.
At Sydney Valves, Dr. Rishi Puri presented data from DurAVR® THV clinical experience, demonstrating a favorable hemodynamic profile for 37 patients sustained to 1-year follow-up.
One-year Results Highlights:
“The one-year data for DurAVR® THV continues to validate its groundbreaking hemodynamic performance, demonstrating sustained excellent effective orifice area (EOA) and low mean gradients. Most notably, this is the only transcatheter valve to show zero prosthesis-patient mismatch (PPM) in small annuli patients—an achievement that sets a new standard in TAVR. PPM is a well-established predictor of valve failure and disease progression, and eliminating it has profound implications for long-term patient outcomes. These results reinforce the transformative potential of DurAVR® as we move toward pivotal trials.” - Christopher Meduri, Anteris Chief Medical Officer
At London Valves 2024, Dr. Pankaj Garg presented cutting-edge cardiac MRI analyses, which compared flow dynamics and LV function between DurAVR® THV recipients and a healthy control group. These promising data highlight the potential of DurAVR® THV to mimic the performance of a healthy aortic valve as a result of the valve's biomimetic design.
Drs. Amar Krishnaswamy, Nicolas Van Mieghem, and Bernard Prendergast review the latest DurAVR® THV MRI flow & LV mass data compared to a healthy control group, exploring the impact of valve design on laminar flow, disease regression, and patient outcomes.
At TCT 2024, Dr. Amar Krishnaswamy presented the latest MRI data analyses which compared flow dynamics and left ventricular function between DurAVR® THV recipients and a matched healthy control group. Here were some of the key takeaways:
In this matched analysis, DurAVR® THV’s biomimetic design provides flow patterns similar to the healthy valve, as measured by flow displacement (FD) and flow reversal ratios (FRR).
LV mass decreased in patients treated with DurAVR® THV compared to baseline, suggesting an improvement in LV unloading.
In this matched analysis, DurAVR® THV restored left ventricle (LV) end-diastolic volume, LV end-systolic volume, and LV mass to similar to healthy controls.
Watch leading experts in the field of TAVR discuss the biomimetic design of the DurAVR® THV and its impact on hemodynamics and blood flow dynamics, presented by Drs. Christopher Meduri, Susheel Kodali, João Cavalcante, Michael Reardon, Nicolas Van Mieghem, Azeem Latib, Anita Asgar and Vinayak Bapat.
Key takeaways included:
We are excited to share the promising results from a valve-in-valve (ViV) study led by Dr. Anita Asgar and recently presented at New York Valves. The data demonstrated restoration of hemodynamic performance in five complex cases in which patients underwent a DurAVR® Transcatheter Heart Valve implantation after their surgical replacement valves failed.
Dr. Asgar emphasized, “This data set of valve-in-valve patients highlights the impact of the DurAVR® valve biomimetic design by restoring these patients’ hemodynamics to the performance of their initial surgical valve and is very encouraging for the wave of valve-in-valve patients that are coming in the future.”
We are pleased to announce new DurAVR® THV First-in-Human study data was presented at New York Valves by imaging expert Dr. João Cavalcante. “When we look at commercially available surgical or TAVR valves, we are still seeing abnormal flow patterns on cardiac MRI. The restoration of laminar flow, as we are seeing with this new DurAVR® THV, is a byproduct of the intrinsic valve design and novel technology, which might have positive downstream implications to the arteries and consequently to ventricle, and ultimately to the patients,” stated Dr. Cavalcante.
In this video, Drs Nicolas Van Mieghem, Christopher Meduri, and Azeem Latib discuss the biomimetic design of the DurAVR® transcatheter heart valve (THV) and its impact on hemodynamics and blood flow dynamics. Learn about:
At SCAI 2024, Dr Azeem Latib presented an update on the DurAVR® THV First-in-Human Study, including consistent hemodynamics and excellent safety profile through 1-year post-implantation.
Learn about:
At CRT 2024, Dr Rishi Puri presented an update on DurAVR® THV. The biomimetic valve is showing consistently promising hemodynamic performance—measured by EOA, MPG, and DVI—from 30 days through 1 year. Learn about DurAVR® THV and view the full presentation on the EFS and FIH studies below.
View the latest investor-related updates
